• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NEJM - Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center

Mary Wilson

New member
March 23, 2021
DOI: 10.1056/NEJMc2102153

William Daniel[SUP] 1[/SUP], Marc Nivet[SUP] 1[/SUP], John Warner[SUP] 1[/SUP], Daniel K Podolsky[SUP] 1[/SUP]

Emergency use authorizations for two messenger RNA (mRNA) vaccines ? the BNT162b2 vaccine (Pfizer?BioNTech) and the mRNA-1273 vaccine (Moderna) ? marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic. These Food and Drug Administration actions were based on impressive results of clinical trials, but only in the weeks since the authorizations has real-world evidence been available to shed light on the overall effect of the vaccines on transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and related illness.

Here, we report data from the University of Texas Southwestern Medical Center (UTSW), which initiated a program on December 15, 2020, to offer vaccine against SARS-CoV-2 to its frontline employees in phase 1a of vaccination, as directed by the Texas Department of State Health Services. The launch of the vaccination effort coincided with a rapidly escalating number of new SARS-CoV-2 infections in North Texas. This escalation led to the largest surge to date in the region and strained health systems.

https://www.nejm.org/doi/full/10.1056/NEJMc2102153
 
Back
Top Bottom